Prelude Therapeutics Incorporated announced a private placement with certain institutional accredited investors for issuance of 7,936,759 pre-funded warrants at a price of $3.1499 per warrant for gross proceeds of $24,999,997.1741 on December 11, 2023. The warrants have an exercise price of $0.0001 per share. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about December 13, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +0.74% | +9.41% | -4.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.68% | 223M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding